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TREATMENT OF DYSLIPIDEMIA IN RENAL DISEASE
Progression of diabetic nephropathy in normotensive type 1
diabetic patients
PETER JACOBSEN, KASPER ROSSING, LISE TARNOW, PETER ROSSING, CHRISTINE MALLET,
ODETTE POIRIER, FRANCOIS CAMBIEN, and HANS-HENRIK PARVING
Steno Diabetes Center, Gentofte, Denmark, and Institut National de la Sante´ et de la Recherche Me´dicale SC7, Paris, France
Progression of diabetic nephropathy in normotensive type 1 rate (GFR): 0 to 24 ml/min/year, mean 12 to 15 ml/min/
diabetic patients. year [1–3]. Several risk factors for loss of filtration power,
Background. The first aim of our long-term study was to so-called progression promoters, have been described indescribe the natural history of diabetic nephropathy in 59 nor-
the above-mentioned studies and in investigations deal-motensive type 1 diabetic patients. Secondly, we evaluated
ing with type 1 diabetic patients receiving antihypertensivegenetic and nongenetic progression promoters.
Methods. The following progression promoters were deter- treatment, as reviewed by Rossing [4]. Numerous trials
mined: the insertion/deletion polymorphism in the angiotensin have demonstrated a beneficial effect of effective lowering
converting enzyme (ACE) gene, blood pressure, albuminuria, of blood pressure (BP) on albuminuria, rate of decline inhemoglobin A1c, cholesterol, smoking, height, and gender. We GFR and the prognosis of diabetic nephropathy [5–9].studied the natural history by measuring 51Cr-EDTA plasma
The progression of renal disease in spontaneously nor-clearance at yearly intervals at least three times during [median
(range)] 5.5 (2.2 to 18.3) years. motensive type 1 diabetic patients suffering from diabetic
Results. At baseline the three groups (II, N 5 11; ID, N 5 nephropathy is not known. This question deserves atten-
25, and DD, N 5 23) had comparable GFR (103 6 16; 99 6 tion, since as many as 25% of type 1 diabetic patients19; 113 6 22 ml/min/1.73 m2, respectively; mean 6 sd), arterial
with this complication are normotensive [6, 10].blood pressure, albuminuria, and hemoglobin A1c. During the
The aim of our long-term observational follow-upfollow-up there was a median rate of decline in GFR in all 59
patients of 1.2 (range 12.9 to –4.4) ml/min/year. During the study was to describe the natural history of diabetic ne-
study period no significant differences were observed in: the phropathy in normotensive type 1 diabetic patients. Fur-
rate of decline in glomerular filtration rate [median (range) thermore, we evaluated genetic and nongenetic progres-0.9 (10.6 to –1.9); 2.5 (12.9 to –4.4); 1.4 (10.8 to –1.9 ml/min/
sion promoters.year)], arterial blood pressure, albuminuria, hemoglobin A1c
or cholesterol between the three groups (II, ID and DD),
respectively. At baseline, multiple linear regression analysis
METHODSincluding the above-mentioned putative risk factors revealed
that albuminuria, short stature, and male gender independently Patients
predict an enhanced decline in GFR [R2 (adjusted) 5 0.33;
We examined the records of all adult Caucasian typeP , 0.002]. During the follow-up period, only albuminuria acted
1 diabetic patients with persistent albuminuria (.200as an independent progression promoter [R2 (adjusted) 5 0.37;
P , 0.0001]. mg/min in 2 out of 3 consecutive determinations carried
Conclusions. Our study revealed a rather slow progression out within a 6-month period) attending the outpatient
of kidney disease in normotensive type 1 diabetic patients with clinic at Steno Diabetes Center between 1993 and 1996
diabetic nephropathy. Albuminuria, short stature, and male
who had diabetic nephropathy and who had their GFRgender act as progression promoters in such patients.
measured during the same period. Diabetic nephropathy
was diagnosed clinically if there were persistent albumin-
uria, diabetic retinopathy, diabetes duration of moreStudies of the natural history of diabetic nephropathy
than 10 years and absence of any clinical or laboratoryhave been carried out in small numbers of mainly hyper-
evidence of other kidney or renal tract disease [11]. Pa-tensive (diastolic BP . 90 mm Hg) patients, revealing
tients fulfillling the following criteria could be enrolled:a large variation in the decrease in glomerular filtration
diabetic nephropathy, normotension, no renoprotective
therapies including angiotensin converting enzyme
(ACE) inhibitors, at least three GFR measurements dur-Key words: angiotensin converting enzyme gene, glomerular filtration
rate, albuminuria, blood pressure, type 1 diabetes. ing at least two years of observation without antihyper-
tensive treatment. Fifty-nine consecutive patients ful- 1999 by the International Society of Nephrology
S-101
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Table 1. Clinical and laboratory data at baseline in 59 normotensive type 1 patients with diabetic nephropathy according to
insertion(I)/ deletion (D) polymorphism in the ACE-gene (ACE/ID genotypes)
II genotype ID genotype DD genotype P value
Sex men/women 7/4 13/12 14/9 NS
Age years 34 (11) 35 (10) 29 (10) NS
Duration of diabetes years 19 (7) 20 (9) 20 (9) NS
N of patients with retinopathy (simplex/proliferative) 8/3 15/10 15/8 NS
Insulin dose IU/kg/24 hr 0.6 (0.1) 0.6 (0.2) 0.7 (0.2) NS
Height cm 173.6 (2.6) 169.6 (1.3) 171.7 (1.6) NS
Body mass index kg/m2 22.8 (1.4) 23.0 (3.3) 23.5 (2.3) NS
Smoking yes/no 4/7 16/9 17/6 NS
GFR ml/min/1.73 m2 103 (16) 99 (19) 113 (22) 0.07
Serum creatinine lmol/litera 72 (66–78) 79 (73–85) 73 (67–79) NS
Blood pressure mm Hg 134/83 (9/5) 135/83 (13/5) 128/79 (11/6) 0.08
Albuminuria lg/mina 550 (332–939) 550 (386–783) 397 (315–501) NS
Hemoglobin A1C% 8.7 (1.5) 8.9 (1.2) 9.0 (1.4) NS
Serum cholesterol mmol/liter 4.9 (0.9) 5.1 (1.2) 5.5 (1.2) NS
Values are means (sd).
a Geometric mean with 95% CI
filled these criteria and all gave fully informed consent. were measured enzymatically using CHOD-PAP rea-
gens from Boehringer-Mannheim GmbH (Mannheim,In our clinic, GFR is measured routinely approximately
once a year from onset of diabetic nephropathy in all Germany). Genotyping was performed as described in
detail previously [14] and subjects were classified ac-type 1 diabetic patients. Baseline data are based on val-
ues from the year of the first GFR measurement (Table cording to the presence (I) or absence (D) of a 287 base
pair insertion in intron 16 of the ACE-gene into II, ID1). Median time from onset of diabetic nephropathy to
first GFR determination was one year (range 0.1 to 9 or DD genotypes. Diabetic retinopathy was assessed by
fundus photography after pupillary dilation. Patientsyears). Arterial hypertension was diagnosed according
to WHO criteria, and antihypertensive medication pre- were on a diabetic diet (45 to 55% carbohydrates, 30 to
35% fat, and 15 to 20% protein) without restriction inscribed if at least three consecutive recordings revealed
a systolic BP .160 mm Hg and/or a diastolic BP .95 sodium or protein intake.
mm Hg. The experimental design was approved by the
Statistical analysislocal ethical committee.
Values are given as means (sd), except for urinary
Methods albumin concentration and serum creatinine, which are
expressed as geometric means with 95% confidence in-Glomerular filtration rate and other physiological in-
vestigations were carried out 3 to 24 (median 7) times terval (CI) owing to the skewed distribution. Other non-
normally distributed variables are given as mediansduring 2.2 to 18.3 (5.5) years (NS between ACE/ID
groups). The GFR was measured applying a single intra- (range). Linear regression analysis was used to assess the
rate of decline in GFR from all values obtained withoutvenous injection of 51Cr-EDTA (3.7 MBq) and thereafter
following the plasma clearance of the tracer for four antihypertensive treatment. Calculations of baseline blood
pressure, urinary albumin excretion rate and HbA1C arehours [12]. The mean day to day coefficient of variation in
GFR in individuals is 4% in our laboratory. The urinary based on all values from the year of the first measure-
ment of GFR. Analysis of the three above-mentionedalbumin concentration was determined by an enzyme
immunoassay during the four-hour clearance period and variables during follow-up are based on all values until
the date of the last GFR measurement included. Forfrom all 24-hour urine collections made at home (about
four times a year) [13]. Arterial blood pressure was mea- normally distributed variables, including logarithmically
transformed values of albuminuria and serum creatinine,sured with a standard clinical mercury sphygmomanome-
ter (cuff 25 cm 3 12 cm) on the right arm while the the three groups were compared by a one-way analysis
of variance (ANOVA). For non-normally distributedpatient was sitting after 10 minutes of rest. Diastolic
blood pressure was recorded at the disappearance of the continuous variables the three groups were compared
by Kruskal–Wallis test. When the patients were dividedKorotkoff sounds (phase V). From venous blood samples
HbA1C concentration (normal range 4.3 to 6.2%) was in two groups comparisons with an unpaired Students
t-test and Mann–Whitney test were used depending ondetermined by high performance liquid chromatography
(DIAMAT Analyzer; Bio-Rad, Richmond, CA, USA). sample size and distribution. Two separate multivariate
stepwise linear regression analyzes of putative risk fac-Serum creatinine concentration was assessed by the ki-
netic Jaffe´ method. Serum cholesterol concentrations tors (at baseline and during the follow-up period) influ-
Jacobsen et al: Progression of diabetic nephropathy S-103
pared to 1.2 (10.8 to 22.3) in the 28 patients who did
not become hypertensive (NS). Baseline and follow-up
BP, HbA1C and albuminuria did not differ between the
two groups. The five patients with II genotype who re-
mained normotensive had a rate of decline in GFR of
0.2 (2.7 to 21.9) ml/min/year compared to 3.0 (12.9 to
24.4) ml/min/year in the 25 patients with ID and DD
who later developed hypertension (P 5 0.16).
At baseline a multiple linear regression analysis of
putative risk factors revealed that albuminuria, short
stature and male gender independently predict an accel-
erated rate of decline in GFR (R2 5 0.33; P , 0.002),
whereas ACE/ID genotype, BP, HbA1C, serum choles-
Fig. 1. Rate of decline in glomerular filtration rate (GFR) versus mean terol concentration and smoking did not contribute sig-arterial blood pressure in 59 normotensive type 1 diabetic patients with
nificantly. The only independent progression promoterdiabetic nephropathy. None of the patients received blood pressure
lowering treatment. Median is indicated by the (X). during the follow-up period was albuminuria [R2 (ad-
justed) 5 0.37; P , 0.0001]. Patients with albuminuria
in the lowest tertiles had rate of decline in GFR of only
[median (range)] 0.2 (10.6 to –4.4) ml/min/year, whereasencing the rate of decline in GFR were performed with
the rate of decline was 3.0 (12.9 to –0.8) ml/min/year inbackward selection. The following putative progression
those patients with albuminuria in the highest tertilespromoters were included in the analyses: ACE/ID geno-
(P , 0.01; Table 3). It should be mentioned that HbA1ctype, BP, albuminuria, HbA1c, cholesterol, smoking,
was nearly identical in the three groups.height and gender. The two latter variables were ex-
cluded in the analysis during the follow-up period. ACE/
ID genotype was entered as an ordered categorical vari- DISCUSSION
able (II 5 1, ID 5 2, DD 5 3) due to the relationship
Our six-year observational follow-up study of normo-between genotype and serum ACE levels. The R2 value
tensive type 1 diabetic patients with diabetic nephropa-is adjusted for the number of levels introduced into the
thy revealed a median loss in GFR of <1 ml/min/year,model. A P-value (two sided) of , 0.05 was considered
a GFR reduction equal to that observed with the naturalto be significant. All calculations were performed using
aging process. Increased baseline albuminuria, short stat-SPSS (SPSS, Chicago, IL, USA).
ure and male gender predicted a steeper rate of decline
in GFR, while albuminuria was the only independent
RESULTS progression promoter during the follow-up period.
To obtain a valid determination of the rate of declineAt baseline the patient groups with different geno-
in GFR in individual patients with chronic progressivetypes were similar with regard to all recorded variables
kidney disease, the following requirements should be(Table 1).
fulfilled: the applied GFR method should have a goodDuring follow-up we demonstrated a rate of decline
accuracy and precision, repeated GFR determinationin GFR in all 59 patients of [median (range)] 1.2 (12.9
should be performed, and the observation period shouldto 24.4) ml/min/year (Fig. 1). No significant difference
be extended to at least two years [15]. These require-in the rate of decline in the GFR between the groups
ments were fulfilled in our study.with different ACE/ID genotypes (II, ID, DD) was ob-
In agreement with previous studies of the natural his-served (ml/min/year): 0.9 (10.6 to –1.9); 2.5 (12.9 to 24.4)
tory of diabetic nephropathy in mainly hypertensive typeand 1.4 (10.8 to 21.9), respectively. The nongenetic pro-
1 diabetic patients [1–3, 16], we found a considerablegression promoters BP, albuminuria, HbA1C and serum
variation in the rate of decline in GFR in our normoten-cholesterol concentration were similar in the three
sive patient group. In an attempt to explain this variationgroups during the whole follow-up of the study (Table 2).
we investigated some genetic and several nongenetic riskThirty-one of the patients (53%) developed hyperten-
factors, so-called progression promoters.sion and therefore had their observation period termi-
Recently, we have shown that hypertensive type 1nated. The time from onset of diabetic nephropathy to
diabetic patients treated with an ACE inhibitor have aantihypertensive medications were prescribed was [me-
rate of decline in GFR of 5.7 ml/min/year if they aredian (range)] 7 (3 to 14) years.
homozygous for the D allele as compared to 2.6 ml/min/The 31 patients who later developed hypertension had
year in patients having the ID or II genotype [17]. Similara rate of decline in GFR of [median (range)] 2.5 (12.9
to 24.4) ml/min/year while still normotensive, as com- findings have been reported in type 2 diabetic patients
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Table 2. Progression of diabetic nephropathy in 59 normotensive type 1 patients according to ACE/ID genotypes
II genotype ID genotype DD genotype P value
Follow-up yearsa 4.2 (2.9 to 12.4) 4.8 (2.2 to 14.1) 7.7 (2.5 to 18.3) NS
Decrease in GFR ml/min/yeara 0.9 (10.6 to 21.9) 2.5 (12.9 to 24.4) 1.4 (10.8 to 21.9) NS
Blood pressure mm Hg 138/82 (10/4) 136/83 (10/6) 134/81 (10/6) NS
Albuminuria lg/minb 786 (438–1410) 574 (423–778) 548 (429–699) NS
Hemoglobin A1C % 8.9 (1.0) 8.7 (1.1) 9.0 (0.7) NS
Serum cholesterol mmol/liter 5.2 (0.9) 5.5 (1.3) 5.2 (1.0) NS
Values are means (sd).
a Median (range)
b Geometric mean with 95% CI
Table 3. Impact of albuminuria on progression of diabetic nephropathy in 59 normotensive type 1 diabetic patients
Tertiles
Lowest Middle Highest P
Albuminuria lg/min ,420 420–809 .809
Decrease in GFR ml/min/yeara 0.2 (10.6 to 24.4) 2.8 (7.9 to 21.9) 3.0 (12.9 to 20.8) ,0.01
Hemoglobin A1C % 8.7 (0.9) 9.0 (0.9) 8.7 (1.1) NS
Values are means (sd).
a Median (range)
with overt nephropathy [18], and in various types of progression promoter both in type 1 and in type 2 dia-
nondiabetic kidney disease [19]. However, in the present betic patients. Remuzzi and Bertani have suggested that
study dealing with normotensive subjects not receiving various types of glomerulosclerosis including diabetic are
BP lowering medication, the ACE/ID polymorphism had the consequence of altered glomerular permeability to
no significant impact on the deterioration of kidney func- proteins [25].
tion. Numerous studies have demonstrated that elevated
The present study is the first to demonstrate that short BP is an important progression promoter in diabetic
stature and male gender act as independent progression nephropathy [2, 9, 16]. However, this impact is reduced
promoter in normotensive type 1 diabetic patients with and sometimes even completely lacking in patients re-
diabetic nephropathy. The concept that low birth weight, ceiving aggressive antihypertensive treatment leading to
known to correlate directly with adult height [20], is normal blood pressure levels [26, 27]. Our study confirms
associated with a reduced number of nephrons and there- and extends this observation to include normotensive
fore may act as a risk factor for renal disease was origi- type 1 diabetic patients not receiving blood pressure
nally suggested by Brenner and Chertow [21]. In support lowering agents.
of this concept two studies have demonstrated an in- In conclusion, our long-term observational study re-
creased risk for development of diabetic nephropathy in vealed a rather slow progression of kidney disease in
women born with a low birth weight [20] and in men normotensive type 1 diabetic patients with diabetic ne-
with short stature [22]. In contrast, it should be men- phropathy. Albuminuria, short stature, and male gender
tioned that we were not able to show that low birth act as progression promoters in such patients.
weight acted as a progression promoter in diabetic ne-
Reprint requests to Dr. H.-H. Parving, Steno Diabetes Center, Nielsphropathy in a group of hypertensive type 1 diabetic
Steensens Vej 2, DK-2820 Gentofte, Denmark.
patients receiving antihypertensive treatment (abstract;
Jacobsen et al, J Am Soc Nephrol 7:1359, 1996). Several
APPENDIXstudies have demonstrated that male gender plays a sig-
nificant role in the progression of several nondiabetic Abbreviations used in this article are: ACE, angiotensin converting
enzyme; ACE/ID, insertion/deletion polymorphism in the angiotensinrenal diseases [23]. The exact mechanism of this relation-
converting enzyme-gene; BP, blood pressure; BMI, body mass index;ship is not known, but differences in renal hemodynamic,
CI, confidence interval; GFR, glomerular filtration rate; HbA1C, hemo-and dietary factors have been proposed [23]. globin A1C; PCR, polymerase chain reaction; type 1 diabetes, insulin-
dependent diabetes mellitus.Albuminuria at baseline and during follow-up was the
strongest independent risk factor for loss of filtration
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